Want to see HK:6996 full AI Analyst Report?
Antengene Corporation Limited (6996) AI Stock Analysis
Top Page
Antengene Corporation Limited
(HKEX:6996)
The score is driven primarily by financial performance: revenue growth and narrowing losses/cash burn are positives, but the company remains loss-making with negative free cash flow. Technical indicators add pressure due to a clear downtrend and negative momentum. Valuation is only modestly supportive given a relatively high P/E and no dividend yield.
Antengene Corporation Limited (6996) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.80B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.13M
- Price to Earnings (P/E)
- 29.6
- Beta (1Y)
- 2.25
- Revenue Growth
- 605.95%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 122
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Antengene Corporation Limited Business Overview & Revenue Model
Company Description
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016...
How the Company Makes Money
Antengene’s revenue model is primarily driven by (1) commercialization of approved products in markets where it has launched or obtained marketing authorizations, and (2) collaboration and out-licensing arrangements related to its drug candidates. Pr...
Antengene Corporation Limited Financial Statement Overview
Summary
Financials show improving momentum but remain high-risk: revenue growth accelerated in 2025 and losses/cash burn narrowed, yet profitability is still deeply negative and free cash flow remains meaningfully negative. Balance sheet leverage is low and improving, but continued losses are eroding shareholder returns.
Income Statement
32NegativeBalance Sheet
58NeutralCash Flow
36Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 558.15M | 105.34M | 91.95M | 67.31M | 160.13M | 28.77M |
| Gross Profit | 510.54M | 86.83M | 74.17M | 55.01M | 132.00M | 24.19M |
| EBITDA | 173.08M | -214.96M | -337.84M | -550.31M | -851.73M | -606.75M |
| Net Income | 50.61M | -239.13M | -319.25M | -581.18M | -601.49M | -655.53M |
Balance Sheet | ||||||
| Total Assets | 1.52B | 1.26B | 1.34B | 1.62B | 2.14B | 2.56B |
| Cash, Cash Equivalents and Short-Term Investments | 764.90M | 734.29M | 900.24M | 1.19B | 1.79B | 2.37B |
| Total Debt | 257.88M | 257.51M | 249.44M | 201.02M | 57.95M | 14.81M |
| Total Liabilities | 605.88M | 614.86M | 493.93M | 471.20M | 428.84M | 163.29M |
| Stockholders Equity | 912.14M | 642.70M | 850.80M | 1.15B | 1.71B | 2.39B |
Cash Flow | ||||||
| Free Cash Flow | -130.28M | -178.86M | -382.57M | -778.87M | -665.56M | -581.04M |
| Operating Cash Flow | -72.82M | -127.51M | -321.96M | -665.77M | -572.18M | -557.65M |
| Investing Cash Flow | -111.55M | 116.16M | 345.24M | 587.07M | -208.16M | -103.88M |
| Financing Cash Flow | 14.28M | -3.19M | 45.17M | 131.84M | -20.73M | -81.29M |
Antengene Corporation Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6996, the sentiment is Negative. The current price of 2.79 is below the 20-day moving average (MA) of 3.06, below the 50-day MA of 3.37, and below the 200-day MA of 3.98, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 34.12 is Neutral, neither overbought nor oversold. The STOCH value of 25.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6996.
Antengene Corporation Limited Peers Comparison
Overall Rating
HK:180181Outperform
HK:996652Neutral
HK:685550.1Neutral
HK:261646.6Neutral- HK:699644Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1801 | 81Outperform | HKD 139.32B | 95.59 | 6.06% | ― | 42.64% | 9.67% |
| HK:9966 | 52Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:6855 | 50Neutral | HKD 10.12B | -5.93 | -153.78% | ― | 70.26% | -12.79% |
| HK:2616 | 47Neutral | HKD 7.77B | -15.53 | -43.54% | ― | 116.67% | -0.42% |
| HK:6996 | 44Neutral | HKD 1.80B | 29.59 | 6.51% | ― | 605.95% | ― |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6996 | Antengene Corporation Limited | 2.79 | -2.33 | -45.51% | |
| HK:1801 | Innovent Biologics | 79.75 | -10.45 | -11.59% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2616 | CStone Pharmaceuticals | 4.94 | -1.28 | -20.58% | |
| HK:6855 | Ascentage Pharma Group International | 27.20 | -40.70 | -59.94% |
Antengene Corporation Limited Corporate Events
Antengene Grants 11.52 Million RSUs Under 2022 Incentive Scheme
Antengene Corporation Limited has granted 11,520,000 restricted share units under its 2022 RSU Scheme to 75 eligible participants, including employees, senior management, executive directors and independent non-executive directors. The RSUs, with no...
Antengene Wins Australian Approval to Begin Phase I Trial of Autoimmune Drug ATG-201
Antengene Corporation Limited has secured Human Research Ethics Committee approval in Australia and completed the Clinical Trial Notification process with the Therapeutic Goods Administration for its Phase I ATTRACT study. The trial will evaluate ATG...
Antengene Swings to Interim Profit on Licensing-Driven Revenue Surge
Antengene Corporation Limited reported a sharp turnaround in its interim results for the six months ended June 30, 2026, driven by a surge in revenue from licensing and collaboration deals. Revenue jumped to RMB513.1 million from RMB53.2 million a ye...
Antengene Sets Board Meeting to Approve 2026 Interim Results
Antengene Corporation Limited has scheduled a board meeting for August 21, 2026 to review and approve the interim results for the six months ended June 30, 2026 and to authorize their publication. The announcement signals upcoming disclosure of the c...
Antengene Updates Board Composition and Committee Roles
Antengene Corporation Limited announced the current composition of its board of directors, led by Chairman and Chief Executive Officer Dr. Jay Mei and executive director Dr. Bing Hou, alongside three independent non-executive directors. The company a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 04, 2026